We have previously demonstrated that interleukin-17A (IL-17) producing T helper 17 cells are significantly elevated in blood and bone marrow (BM) in multiple myeloma (MM) and IL-17A promotes MM ...
Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biopharmaceutical company specializing in diagnostic substances with a market ...
Immunotherapy. 2013;5(9):923-925. Rather than focusing on the blockade of IL-17A or IL-17F alone, Wedebye Schmidt et al. examined the effects of blockade of both IL-17A and IL-17F. They report ...
Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...
Hosted on MSN1mon
UCB gets FDA approval for Bimzelx for hidradenitis suppurativaThe company said Bimzelx is now the first IL-17A and IL-17F inhibitor approved for the condition. Bimzelx is also FDA approved for the treatment of plaque psoriasis, psoriatic arthritis ...
MoonLake Immunotherapeutics (MLTX) announced that patients have been screened in three new trials across three new indications to evaluate ...
The following is a summary of “Biomarkers of oxidation, inflammation and intestinal permeability in persons with diabetes mellitus with parenteral nutrition: A multicenter randomized trial,” published ...
在1月20日，令人振奋的消息传来，智翔金泰的1类新药赛立奇单抗（GR1501注射液）新适应症正式在国内获批上市，这款药物专门用于治疗放射学阳性中轴型脊柱关节炎，大家熟知的强直性脊柱炎患者有救了！
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback